170 related articles for article (PubMed ID: 38381664)
1. A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
Hirschfield GM; Bowlus CL; Mayo MJ; Kremer AE; Vierling JM; Kowdley KV; Levy C; Villamil A; Ladrón de Guevara Cetina AL; Janczewska E; Zigmond E; Jeong SH; Yilmaz Y; Kallis Y; Corpechot C; Buggisch P; Invernizzi P; Londoño Hurtado MC; Bergheanu S; Yang K; Choi YJ; Crittenden DB; McWherter CA;
N Engl J Med; 2024 Feb; 390(9):783-794. PubMed ID: 38381664
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
Kowdley KV; Bowlus CL; Levy C; Akarca US; Alvares-da-Silva MR; Andreone P; Arrese M; Corpechot C; Francque SM; Heneghan MA; Invernizzi P; Jones D; Kruger FC; Lawitz E; Mayo MJ; Shiffman ML; Swain MG; Valera JM; Vargas V; Vierling JM; Villamil A; Addy C; Dietrich J; Germain JM; Mazain S; Rafailovic D; Taddé B; Miller B; Shu J; Zein CO; Schattenberg JM; ;
N Engl J Med; 2024 Feb; 390(9):795-805. PubMed ID: 37962077
[TBL] [Abstract][Full Text] [Related]
3. Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.
Jones D; Boudes PF; Swain MG; Bowlus CL; Galambos MR; Bacon BR; Doerffel Y; Gitlin N; Gordon SC; Odin JA; Sheridan D; Wörns MA; Clark V; Corless L; Hartmann H; Jonas ME; Kremer AE; Mells GF; Buggisch P; Freilich BL; Levy C; Vierling JM; Bernstein DE; Hartleb M; Janczewska E; Rochling F; Shah H; Shiffman ML; Smith JH; Choi YJ; Steinberg A; Varga M; Chera H; Martin R; McWherter CA; Hirschfield GM
Lancet Gastroenterol Hepatol; 2017 Oct; 2(10):716-726. PubMed ID: 28818518
[TBL] [Abstract][Full Text] [Related]
4. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
Hirschfield GM; Shiffman ML; Gulamhusein A; Kowdley KV; Vierling JM; Levy C; Kremer AE; Zigmond E; Andreone P; Gordon SC; Bowlus CL; Lawitz EJ; Aspinall RJ; Pratt DS; Raikhelson K; Gonzalez-Huezo MS; Heneghan MA; Jeong SH; Ladrón de Guevara AL; Mayo MJ; Dalekos GN; Drenth JPH; Janczewska E; Leggett BA; Nevens F; Vargas V; Zuckerman E; Corpechot C; Fassio E; Hinrichsen H; Invernizzi P; Trivedi PJ; Forman L; Jones DEJ; Ryder SD; Swain MG; Steinberg A; Boudes PF; Choi YJ; McWherter CA;
Hepatology; 2023 Aug; 78(2):397-415. PubMed ID: 37386786
[TBL] [Abstract][Full Text] [Related]
5. A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
Bowlus CL; Galambos MR; Aspinall RJ; Hirschfield GM; Jones DEJ; Dörffel Y; Gordon SC; Harrison SA; Kremer AE; Mayo MJ; Thuluvath PJ; Levy C; Swain MG; Neff GW; Sheridan DA; Stanca CM; Berg CP; Goel A; Shiffman ML; Vierling JM; Boudes P; Steinberg A; Choi YJ; McWherter CA
J Hepatol; 2022 Aug; 77(2):353-364. PubMed ID: 35367282
[TBL] [Abstract][Full Text] [Related]
6. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
Schattenberg JM; Pares A; Kowdley KV; Heneghan MA; Caldwell S; Pratt D; Bonder A; Hirschfield GM; Levy C; Vierling J; Jones D; Tailleux A; Staels B; Megnien S; Hanf R; Magrez D; Birman P; Luketic V
J Hepatol; 2021 Jun; 74(6):1344-1354. PubMed ID: 33484775
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.
Hirschfield GM; Mason A; Luketic V; Lindor K; Gordon SC; Mayo M; Kowdley KV; Vincent C; Bodhenheimer HC; Parés A; Trauner M; Marschall HU; Adorini L; Sciacca C; Beecher-Jones T; Castelloe E; Böhm O; Shapiro D
Gastroenterology; 2015 Apr; 148(4):751-61.e8. PubMed ID: 25500425
[TBL] [Abstract][Full Text] [Related]
8. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.
Nevens F; Andreone P; Mazzella G; Strasser SI; Bowlus C; Invernizzi P; Drenth JP; Pockros PJ; Regula J; Beuers U; Trauner M; Jones DE; Floreani A; Hohenester S; Luketic V; Shiffman M; van Erpecum KJ; Vargas V; Vincent C; Hirschfield GM; Shah H; Hansen B; Lindor KD; Marschall HU; Kowdley KV; Hooshmand-Rad R; Marmon T; Sheeron S; Pencek R; MacConell L; Pruzanski M; Shapiro D;
N Engl J Med; 2016 Aug; 375(7):631-43. PubMed ID: 27532829
[TBL] [Abstract][Full Text] [Related]
9. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Thompson D; Richards D; Storey J; Dukes GE; Corrigan M; Oude Elferink RP; Beuers U; Hirschfield GM; Jones DE
Lancet; 2017 Mar; 389(10074):1114-1123. PubMed ID: 28187915
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study.
Trauner M; Nevens F; Shiffman ML; Drenth JPH; Bowlus CL; Vargas V; Andreone P; Hirschfield GM; Pencek R; Malecha ES; MacConell L; Shapiro D
Lancet Gastroenterol Hepatol; 2019 Jun; 4(6):445-453. PubMed ID: 30922873
[TBL] [Abstract][Full Text] [Related]
11. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.
Corpechot C; Chazouillères O; Rousseau A; Le Gruyer A; Habersetzer F; Mathurin P; Goria O; Potier P; Minello A; Silvain C; Abergel A; Debette-Gratien M; Larrey D; Roux O; Bronowicki JP; Boursier J; de Ledinghen V; Heurgue-Berlot A; Nguyen-Khac E; Zoulim F; Ollivier-Hourmand I; Zarski JP; Nkontchou G; Lemoinne S; Humbert L; Rainteau D; Lefèvre G; de Chaisemartin L; Chollet-Martin S; Gaouar F; Admane FH; Simon T; Poupon R
N Engl J Med; 2018 Jun; 378(23):2171-2181. PubMed ID: 29874528
[TBL] [Abstract][Full Text] [Related]
12. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
Kowdley KV; Vuppalanchi R; Levy C; Floreani A; Andreone P; LaRusso NF; Shrestha R; Trotter J; Goldberg D; Rushbrook S; Hirschfield GM; Schiano T; Jin Y; Pencek R; MacConell L; Shapiro D; Bowlus CL;
J Hepatol; 2020 Jul; 73(1):94-101. PubMed ID: 32165251
[TBL] [Abstract][Full Text] [Related]
13. Ursodeoxycholic acid for primary biliary cirrhosis.
Rudic JS; Poropat G; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD000551. PubMed ID: 23235576
[TBL] [Abstract][Full Text] [Related]
14. Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis.
Kremer AE; Mayo MJ; Hirschfield G; Levy C; Bowlus CL; Jones DE; Steinberg A; McWherter CA; Choi YJ
Liver Int; 2022 Jan; 42(1):112-123. PubMed ID: 34403559
[TBL] [Abstract][Full Text] [Related]
15. Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial.
de Vries E; Bolier R; Goet J; Parés A; Verbeek J; de Vree M; Drenth J; van Erpecum K; van Nieuwkerk K; van der Heide F; Mostafavi N; Helder J; Ponsioen C; Oude Elferink R; van Buuren H; Beuers U;
Gastroenterology; 2021 Feb; 160(3):734-743.e6. PubMed ID: 33031833
[TBL] [Abstract][Full Text] [Related]
16. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
Reig A; Sesé P; Parés A
Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567
[TBL] [Abstract][Full Text] [Related]
17. Natural history of pruritus in primary biliary cirrhosis.
Talwalkar JA; Souto E; Jorgensen RA; Lindor KD
Clin Gastroenterol Hepatol; 2003 Jul; 1(4):297-302. PubMed ID: 15017671
[TBL] [Abstract][Full Text] [Related]
18. Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.
Mayo MJ; Vierling JM; Bowlus CL; Levy C; Hirschfield GM; Neff GW; Galambos MR; Gordon SC; Borg BB; Harrison SA; Thuluvath PJ; Goel A; Shiffman ML; Swain MG; Jones DEJ; Trivedi P; Kremer AE; Aspinall RJ; Sheridan DA; Dörffel Y; Yang K; Choi YJ; McWherter CA
Aliment Pharmacol Ther; 2024 Jan; 59(2):186-200. PubMed ID: 37904314
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy.
Babatin MA; Sanai FM; Swain MG
Aliment Pharmacol Ther; 2006 Sep; 24(5):813-20. PubMed ID: 16918885
[TBL] [Abstract][Full Text] [Related]
20. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA.
Hirschfield GM; Beuers U; Kupcinskas L; Ott P; Bergquist A; Färkkilä M; Manns MP; Parés A; Spengler U; Stiess M; Greinwald R; Pröls M; Wendum D; Drebber U; Poupon R
J Hepatol; 2021 Feb; 74(2):321-329. PubMed ID: 32950590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
